Repare Therapeutics Reports Proof of Concept for Lunresertib

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib

Monotherapy antitumor activity observed, including confirmed... | June 7, 2023

Related Keywords

Canada , Canadian , Maria Koehler , Lloydm Segal , Company Nasdaq , Repare Therapeutics Inc , Princess Margaret Cancer Center , Company Virtual Webcast Event , Canadian Cancer Trials Group , Repare Therapeutics , Chief Medical Officer , Chief Executive Officer , Initial Findings , Virtual Webcast Event , Repare Therapeutics Inc Stock Exchange , News , Information , Press Release , Findings , Rom , The , Ngoing , Hase , , Mythic , Study , Remonstrated , Favorable , End , Distinctive , Tolerability , Profile , Or , Monotherapy , Antitumor , Activity , Ncluding Rptx Us7602731025 ,